The study marks a significant step forward in the search for treatments that can effectively target prostate cancer while reducing side effects.
Prostate cancer is the most common cancer in men in the UK. Many men diagnosed with intermediate-risk prostate cancer on one side of the prostate currently receive radical treatments, which treat the whole prostate gland. While these treatments—such as surgery or radiotherapy—are effective, they can also lead to side effects that impact quality of life, including urinary and sexual function.
The PART study is exploring a new approach called Partial Ablation, which only treats the affected side of the prostate. By using advanced techniques such as High Intensity Focused Ultrasound (HIFU) and Irreversible Electroporation (IRE or NanoKnife), the trial aims to determine whether this method can effectively treat cancer while better preserving normal continence and sexual function. Researchers think that Partial Ablation will lead to fewer side effects compared to traditional radical treatments.
The study will directly compare these two approaches to see how well they prevent cancer from returning or spreading, and to assess their impact on patients’ daily lives. With 800 participants expected to take part from hospitals across the UK, the findings will help future patients, doctors, and policymakers make informed decisions about prostate cancer treatment.
Dr Uwais Mufti Consultant Urologist at ĢtvƵ said:
“Prostate cancer treatment has come a long way, but we are always striving to improve outcomes while minimizing side effects. The PART study is an exciting trial that will provide high quality evidence and establish whether targeted treatments could offer men a better quality of life without compromising effectiveness. By comparing Partial Ablation with traditional radical treatments, we aim to provide valuable insights that will shape the future of prostate cancer care internationally.”
For more information about the PART study, please email or call 01132068997.